Rho-family GTPase (Rho GTPase) (Rho GTPase)

Rho-family GTPases are a family of small signaling G proteins belonging to the Ras superfamily that function as molecular switches, cycling between an active GTP-bound state and an inactive GDP-bound state [UniProt]. They are primary regulators of the actin cytoskeleton, controlling fundamental cellular processes such as cell shape, polarity, and movement [Science, 1998]. Beyond structural organization, they influence gene transcription, cell cycle progression, and vesicle trafficking [Nature, 2002]. In clinical contexts, Rho GTPases are frequently dysregulated in cancer, where they drive tumor cell invasion, metastasis, and drug resistance [FEBS Letters, 2008]. While direct inhibition of these proteins is challenging due to their high affinity for GTP, therapeutic strategies include targeting downstream effectors like Rho-associated protein kinase (ROCK) or inhibiting post-translational modifications like geranylgeranylation that are required for their membrane attachment [EMBO Reports, 2012]. These proteins also play roles in cardiovascular and neurological diseases, making them versatile but complex therapeutic targets [Frontiers in Cardiovascular Medicine, 2021]. Current research focuses on developing more selective small-molecule inhibitors to minimize off-target effects associated with their ubiquitous expression [Cancer Research, 2018]. The family includes well-known members such as RhoA, Rac1, and Cdc42, each with distinct but overlapping roles in cellular signaling [J Cell Sci, 2005]. Pharmacological intervention in this pathway has already seen clinical success in treating conditions like glaucoma and cerebral vasospasm [StatPearls]. Future therapeutic development aims to refine the specificity of inhibitors to better manage the pleiotropic effects of Rho signaling [EMBO Reports, 2012].

Other names

Ras-homologous GTPasesRho proteinsSmall GTP-binding proteinsRho family of GTPases

Pharmacological modulation of Rho-family GTPases involves several strategies: direct inhibition of the GTP-binding site, disruption of the interaction between the GTPase and its specific Guanine Nucleotide Exchange Factor (GEF), or inhibition of the geranylgeranyltransferase enzyme to prevent the post-translational lipid modification necessary for membrane anchoring [EMBO Reports, 2012; Cancer Research, 2018]. Additionally, many clinical applications focus on inhibiting downstream effectors, most notably Rho-associated protein kinase (ROCK), to block the signaling cascades initiated by active Rho proteins [EMBO Reports, 2012].